Extended Data Fig. 10: Treatment of B16-F10 tumors by the Se9-TRP1-CAR T cell and anti-PD-1 combination.
a, Treatment with anti-PD-1 antibody or TRP1-CAR T cells alone had no inhibitory effect on the growth of B16-F10 tumors. b, Growth curves of B16-F10 tumors in mice with indicated treatments. c, B16-F10 tumor weights with indicated treatments. d, Survival curves of mice with indicated treatments. e, The number of TRP1-CAR T cells or Se9-TRP1-CAR T cells in tumors for each group of mice quantified based on flow cytometry analysis. f, The percentage of live TRP1-CAR T cells or Se9-TRP1-CAR T cells in total live cells from B16-F10 tumors with indicated treatment as quantified from flow cytometry analysis. g, The percentage of GzmB+ TRP1-CAR T cells as quantified by flow cytometry. h, The percentage of Ki-67+ TRP1-CAR T cells as quantified by flow cytometry. i, The combination of Se9-TRP1-CAR T cell with anti-PD-1 antibody showed no significant effect on the body weight of B16-F10 tumor-bearing mice. Data represent mean ± SD (n = 7). Statistical analysis was performed using Welch ANOVA with Dunnett T3 multiple comparison tests (a-c, e-i), or log-rank tests (d).
